Want to see APVO full AI Analyst Report?

Aptevo Therapeutics (APVO) Price & Analysis

744 Followers

APVO Stock Chart & Stats

$0.61

-$0.30(-5.81%)

At close: Jan 08 4:00 PM EST

$0.61

-$0.30(-5.81%)

Day’s Range― - ―

52-Week Range$3.80 - $59.40

Previous CloseN/A

Volume25.11K

Average Volume (3M)11.64M

Market Cap

$5.57M

Enterprise Value$393.91K

Total Cash (Recent Filing)$14.53M

Total Debt (Recent Filing)$4.42M

Price to Earnings (P/E)―

Beta-0.04

Next Earnings

Aug 06, 2026

EPS Estimate

-6.02

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-357.16

Shares Outstanding1,246,105

10 Day Avg. Volume7,942,705

30 Day Avg. Volume11,635,265

Financial Highlights & Ratios

PEG Ratio<0.01

Price to Book (P/B)<0.01

Price to Sales (P/S)0.00

P/FCF Ratio>-0.01

Enterprise Value/Market Cap0.07

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-3.40

Enterprise Value/Ebitda-0.02

Forecast

1Y Price Target

$21.00

Price Target Upside3342.62% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)-24.13

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Proprietary Multispecific PlatformAptevo’s ADAPTIR/ADAPTIR-FLEX multispecific antibody platforms represent a durable technical moat, enabling differentiated multi-specific therapeutics across oncology indications. Platform-driven candidate generation increases partnerability, supports multiple programs, and underpins recurring licensing or collaboration opportunities over time.

Compelling Clinical Validation In AMLStrong Phase 1b RAINIER results (high benefit/remission rates and favorable safety) materially de-risk mipletamig's development path and validate Aptevo's differentiated CD123 approach. Durable impact: supports orphan designation, strengthens strategic positioning vs standard of care, and improves attractiveness for partnerships or later-stage investment.

Pipeline Diversification Via Radiopharmaceutical CollaborationThe Niowave partnership diversifies Aptevo’s pipeline into targeted radiopharmaceuticals, combining multispecific antibodies with scarce isotope capability. Equity alignment and reciprocal IP/licensing broaden development resources, increase program optionality, and create a durable strategic avenue beyond conventional biologics.

Bears Say

Absent Revenue And Persistent LossesThe structural absence of recurring revenue combined with sizable TTM losses and cash burn means operations depend on external financing or milestone receipts. Over months this elevates dilution risk, constrains R&D sequencing, and limits the company's ability to self-fund multiple concurrent development programs without partnering or capital raises.

Negative Operating Cash Flow And Runway PressureSustained negative operating cash flow reflects limited internal funding capacity and ongoing burn. This structural cash deficit reduces strategic flexibility, can delay IND-enabling or pivotal studies absent new funding, and increases reliance on non-dilutive grants, partners, or dilutive financings to sustain operations over the next 2–6 months.

Clinical-stage Business Model With Binary OutcomesAs a clinical-stage biotech with no marketed products, Aptevo faces inherently binary development risk where long timelines and trial outcomes determine future cash flows. This structural profile makes revenue lumpy and unpredictable, heightens dependence on successful readouts or deals, and increases sensitivity to clinical setbacks.

Aptevo Therapeutics News

Aptevo Therapeutics awarded $1.5M research grant from Andy Hill CARE Fund

Aptevo Therapeutics (APVO) announced it has been awarded a $1.5M non-dilutive research grant from the Andy Hill Cancer...

4d ago

APVO

Aptevo Therapeutics Secures Grant for APVO451 Development

Aptevo Therapeutics ( ($APVO) ) has shared an update. On June 29, 2026, Aptevo Therapeutics entered a Grant...

4d ago

APVO

Aptevo Therapeutics appoints Janatpour as SVP, CSO

Aptevo Therapeutics (APVO) announced the appointment of Mary Janatpour, Ph.D., as Senior Vice President, SVP, and Chief Scientific...

1M ago

APVO

Aptevo Forms Strategic Radiopharmaceutical Collaboration with Niowave

Aptevo Therapeutics ( ($APVO) ) has provided an announcement. On May 25, 2026, Aptevo Research and Development LLC,...

1M ago

APVO

Aptevo, Niowave launch collab for radiopharmaceutical oncology programs

Aptevo Therapeutics (APVO) and Niowave announced a 50/50 strategic collaboration to develop up to three radiopharmaceutical oncology programs....

1M ago

APVO

Aptevo Therapeutics reports Q1 cash and cash equivalents $14.5M

“Aptevo is entering a defining period as a company, supported by growing clinical momentum, a committed leadership team,...

2M ago

APVO

Aptevo reports 87% clinical benefit in frontline AML patients in RAINIER trial

Aptevo Therapeutics (APVO) reported new clinical results from its RAINIER frontline acute myeloid leukemia trial. The company is...

2M ago

APVO

Aptevo Highlights Strong Phase 1b AML Trial Results

Aptevo Therapeutics ( ($APVO) ) has provided an update. On May 6, 2026, Aptevo reported new data from...

2M ago

APVO

Aptevo Therapeutics reports FY25 EPS ($87.27) vs. ($31,460.23) last year

“2025 was a year of meaningful progress across our clinical programs, pipeline strategy and capital position,” said Marvin...

3M ago

APVO

Aptevo Therapeutics sees cash runway into 4Q26

Aptevo ended 2025 with $21.6 million in cash and cash equivalents, compared with $8.7 million at December 31,...

3M ago

APVO

Aptevo Reports Promising Interim Data for AML Therapy

An announcement from Aptevo Therapeutics ( ($APVO) ) is now available. On March 10, 2026, Aptevo Therapeutics reported...

4M ago

APVO

Aptevo Therapeutics announces interim data for mipletamig combination

Aptevo Therapeutics (APVO) announced new interim data for mipletamig in combination with venetoclax and azacitidine in newly diagnosed...

4M ago

APVO

Aptevo Therapeutics Shareholders Approve Expanded Equity Financing Capacity

Aptevo Therapeutics ( ($APVO) ) has shared an update. On February 18, 2026, Aptevo Therapeutics Inc. held a...

5M ago

APVO

Aptevo Therapeutics Announces CEO Transition and Leadership Changes

Aptevo Therapeutics ( ($APVO) ) has provided an announcement. On February 3, 2026, Aptevo Therapeutics announced that President...

5M ago

APVO

APVO FAQ

What was Aptevo Therapeutics Inc’s price range in the past 12 months?

Aptevo Therapeutics Inc lowest stock price was $3.80 and its highest was $59.40 in the past 12 months.

What is Aptevo Therapeutics Inc’s market cap?

Aptevo Therapeutics Inc’s market cap is $5.57M.

When is Aptevo Therapeutics Inc’s upcoming earnings report date?

Aptevo Therapeutics Inc’s upcoming earnings report date is Aug 06, 2026 which is in 33 days.

How were Aptevo Therapeutics Inc’s earnings last quarter?

Aptevo Therapeutics Inc released its earnings results on May 07, 2026. The company reported -$6.41 earnings per share for the quarter, missing the consensus estimate of -$5.6 by -$0.81.

Is Aptevo Therapeutics Inc overvalued?

According to Wall Street analysts Aptevo Therapeutics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Aptevo Therapeutics Inc pay dividends?

Aptevo Therapeutics Inc does not currently pay dividends.

What is Aptevo Therapeutics Inc’s EPS estimate?

Aptevo Therapeutics Inc’s EPS estimate is -6.02.

How many shares outstanding does Aptevo Therapeutics Inc have?

Aptevo Therapeutics Inc has 1,246,105 shares outstanding.

What happened to Aptevo Therapeutics Inc’s price movement after its last earnings report?

Aptevo Therapeutics Inc reported an EPS of -$6.41 in its last earnings report, missing expectations of -$5.6. Following the earnings report the stock price went down -1.619%.

Which hedge fund is a major shareholder of Aptevo Therapeutics Inc?

Currently, no hedge funds are holding shares in APVO

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Aptevo Therapeutics Inc

Aptevo Therapeutics Inc. is a clinical-stage biotechnology company primarily focused on pioneering immunotherapeutic agents for a variety of cancer treatments across the United States. Its foremost investigational drug, APVO436, is a bispecific antibody crafted to engage T-cells, which is currently undergoing a Phase 1b clinical study for acute myeloid leukemia and myelodysplastic syndromes. Beyond its lead asset, Aptevo's research pipeline encompasses several preclinical compounds. These include ALG.APV-527, an experimental bispecific ADAPTIR molecule designed to target both 4-1BB (CD137) and 5T4, a tumor-specific antigen prevalent in numerous cancer types. Another promising candidate is APVO603, a dual agonist bispecific antibody that targets both 4-1BB and OX40. The company is also advancing APVO442, a bispecific agent leveraging its ADAPTIR-FLEX platform technology to improve the precise delivery of drugs to prostate-specific membrane antigen (PSMA)-positive tumors for the treatment of prostate cancer. To further its development efforts for ALG.APV-527, Aptevo maintains a collaborative partnership and option agreement with Alligator Bioscience AB. Founded in 2016, Aptevo Therapeutics Inc. operates from its headquarters located in Seattle, Washington.

Aptevo Therapeutics (APVO) Earnings & Revenues

Historic Earnings Reports

APVO Stock 12 Month Forecast

Average Price Target

$21.00

▲(3342.62% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"$3","54":"$54","15.75":"$15.75","28.5":"$28.5","41.25":"$41.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":21,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$21.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":21,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$21.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":21,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$21.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3,15.75,28.5,41.25,54],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.45,5.723076923076923,6.996153846153847,8.26923076923077,9.542307692307693,10.815384615384616,12.08846153846154,13.361538461538462,14.634615384615387,15.907692307692308,17.180769230769233,18.453846153846154,19.72692307692308,{"y":21,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.45,5.723076923076923,6.996153846153847,8.26923076923077,9.542307692307693,10.815384615384616,12.08846153846154,13.361538461538462,14.634615384615387,15.907692307692308,17.180769230769233,18.453846153846154,19.72692307692308,{"y":21,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.45,5.723076923076923,6.996153846153847,8.26923076923077,9.542307692307693,10.815384615384616,12.08846153846154,13.361538461538462,14.634615384615387,15.907692307692308,17.180769230769233,18.453846153846154,19.72692307692308,{"y":21,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":53.1,"date":1751328000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":48.24,"date":1754006400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":29.52,"date":1756684800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":25.02,"date":1759276800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":27.9,"date":1761955200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":23.76,"date":1764547200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":9.43,"date":1767225600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":7.54,"date":1769904000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":7.09,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.17,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.92,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.24,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.45,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >